Premium
Multicenter trial of naloxone in alzheimer's disease
Author(s) -
Henderson V. W.,
Roberts E.,
Wimer C.,
Bardolph E. L.,
Chui H. C.,
Damasio A. R.,
Eslinger P. J.,
Folstein M. F.,
Schneider L. S.,
Teng E. L.,
Tune L. E.,
Weiner L. P.,
Whitehouse P. J.
Publication year - 1989
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410250413
Subject(s) - (+) naloxone , alzheimer's disease , medicine , multicenter study , disease , neuroscience , psychology , opioid , randomized controlled trial , receptor
In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.